Get the Stockscreener App
17.99
7.12%
-1.38
Neurogene Inc stock is traded at $17.99, with a volume of 313.26K.
It is down -7.12% in the last 24 hours and up +67.04% over the past month.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
See More
Previous Close:
$19.37
Open:
$18.2
24h Volume:
313.26K
Relative Volume:
1.20
Market Cap:
$256.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+22.13%
1M Performance:
+67.04%
6M Performance:
-47.88%
1Y Performance:
-46.65%
1-Day Range:
$15.68
$18.89
1-Week Range:
$13.93
$19.51
52-Week Range:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
17.99 | 210.08M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com Nigeria
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World
Neurogene Shares Drop After Downgrade From Baird - marketscreener.com
Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha
Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus
Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com Nigeria
Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World
Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com
HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus
Wells Fargo & Company MN Purchases 1,397 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Barclays PLC Has $401,000 Position in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Q1 Earnings Snapshot - San Francisco Chronicle
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2025 - BioSpace
Neurogene Reports Q1 2025 Financial Results and Advances Rett Syndrome Gene Therapy - TipRanks
NEUROGENE Earnings Results: $NGNE Reports Quarterly Earnings - Nasdaq
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
Daily Market Movement: Neurogene Inc (NGNE) Sees a -13.63 Decrease, Closing at 13.05 - DWinneX
10,475 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Mariner LLC - Defense World
Neurogene Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView
Neurogene (NGNE) Expected to Announce Earnings on Friday - Defense World
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting - BioSpace
Neurogene Announces Upcoming Oral Presentation On Monitoring And Treatment To Reverse Rare Complication Of High Dose Gene Therapy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Neurogene Inc. (NGNE)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Neurogene Inc. (NASDAQ:NGNE) Shares Acquired by Geode Capital Management LLC - Defense World
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $47.20 - Defense World
Wellington Management Group LLP Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - The AM Reporter
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform By Investing.com - Investing.com South Africa
Wellington Management Group LLP Increases Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
JPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NASDAQ:NGNE) Given New $16.00 Price Target at BMO Capital Markets - Defense World
Neurogene Inc. Amends Agreement, Issues Warrants By Investing.com - Investing.com South Africa
Neurogene Inc. Amends Agreement, Issues Warrants - Investing.com
Neurogene Amends Agreement With Baker Bros To Increase Nomination Threshold - marketscreener.com
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform - Investing.com Canada
NGNE Stock Sees Decline of Approximately -13.67% in Last Five Days - knoxdaily.com
NGNE stock touches 52-week low at $8.35 amid market challenges - Investing.com Australia
NGNE stock touches 52-week low at $8.35 amid market challenges By Investing.com - Investing.com South Africa
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - BioSpace
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.54%
7.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):